Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab and Bevacizumab for Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
INCLUSION CRITERIA:~To be eligible, the following inclusion criteria must be met, where applicable.~1. Participant is 18 years of age or older.~2. Participant has a diagnosis of diabetic mellitus (type 1 or type 2). Any one of the following will be considered to be sufficient evidence that diabetes is present:~   * Current regular use of insulin for the treatment of diabetes;~  * Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes;~  * Documented diabetes by American Diabetes Association (ADA) and/or World Health Organization (WHO) criteria.~3. Participant must understand and sign the protocol's informed consent document.~4. Female participants of childbearing potential must not be pregnant or breast-feeding and must have a negative pregnancy test at screening and must agree to pregnancy testing throughout the study.~5. Female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must agree to practice two acceptable methods of contraception throughout the course of the study and for four weeks after their last injection. Acceptable methods of contraception include:~   * Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring),~  * Intrauterine device,~  * Barrier methods (i.e., diaphragm, condom) with spermicide, or~  * Tubal ligation.~6. Participant has at least one eye that meets the study eye eligibility criteria.~EXCLUSION CRITERIA:~A participant is not eligible if any of the following exclusion criteria are present.~1. Participant is in another investigational study and actively receiving investigational product for DME.~2. Participant has a known hypersensitivity to sodium fluorescein dye.~3. Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).~4. Participant has a history of chronic renal failure requiring dialysis or kidney transplant.~5. Participant has a history of liver failure.~6. Participant has a known hypersensitivity to bevacizumab, ranibizumab or any of their components.~7. Participant has a blood pressure of \> 180/110 (systolic above 180 OR diastolic above 110).~   --If blood pressure is brought below 180/110 by anti-hypertensive treatment, a patient can become eligible.~8. Participant has a history of treatment with oral steroids (greater than or equal to 10 mg of prednisone daily or equivalent) within three months prior to enrollment. Non-ocular depot and inhaled steroid treatments will not exclude a participant.~9. Participant has a history of treatment with systemic anti-VEGF agents within four weeks prior to enrollment.~STUDY EYE ELIGIBILITY CRITERIA:~The participant must have at least one eye meeting all inclusion criteria and none of the exclusion criteria listed below. Participants for whom both eyes meet all of the inclusion criteria and none of the exclusion criteria listed below may have both eyes enrolled in the study if they and the investigator so choose. If both eyes meet all of the inclusion criteria and none of the exclusion criteria listed below, and if the participant and the investigator decide that only one eye should be enrolled in the study, the study eye will be selected by the investigator in consultation with the participant.~STUDY EYE INCLUSION CRITERIA:~1. Eye has a BCVA ETDRS score between 20/32 and 20/400.~2. Eye has definite retinal thickening or cystic changes due to DME based on clinical exam involving the center of the macula that is not refractory to further therapy as based on the investigator's clinical judgment.~3. Eye has retinal thickness in the central subfield on baseline OCT measurement greater than or equal to 330 microns, as measured by Cirrus OCT.~4. Eye has clear ocular media and adequate pupillary dilation sufficient for adequate fundus photographs.~STUDY EYE EXCLUSION CRITERIA:~1. Eye has macular edema considered to be due to a cause other than diabetes.~   An eye is not eligible if:~  * The macular edema is considered to be related to cataract extraction; or~  * Clinical examination and/or OCT suggest that vitreoretinal interface disease (e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular edema.~2. Eye has an ocular condition present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, non-retinal condition).~3. Eye has an ocular condition present (other than DR) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.).~4. Eye has a history of panretinal scatter photocoagulation (PRP) within three months prior to enrollment.~5. Eye has a history of prior pars plana vitrectomy prior to enrollment.~6. Eye has a history of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within three months prior to enrollment.~7. Eye has a history of Yttrium-Aluminum-Garnet (YAG) capsulotomy performed within two months prior to enrollment.~8. Eye had laser photocoagulation treatment, or received intravitreal or periocular steroids within three months prior to enrollment.~9. Eye has a history of intravitreal anti-VEGF agents within eight weeks prior to enrollment.~10. Eye has had greater than four intravitreal anti-VEGF injections within one year prior to enrollment.~11. Eye has high-risk proliferative DR requiring laser photocoagulation treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 - Ranibizumab-Ranibizumab-Bevacizumab Injection Series (Type: EXPERIMENTAL): Group 1 eyes were assigned to Ranibizumab-Ranibizumab-Bevacizumab (RRB) treatment sequence and received intravitreal injections of ranibizumab at baseline, Weeks 4, and 8 (period 1), and Weeks 12, 16 and 20 (period 2), then crossed over to receive intravitreal injections of bevacizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye.
- Group 2 - Ranibizumab-Bevacizumab-Bevacizumab Injection Series (Type: EXPERIMENTAL): Group 2 eyes were assigned to Ranibizumab-Bevacizumab-Bevacizumab (RBB) treatment sequence and received intravitreal injections of ranibizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of bevacizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye.
- Group 3 - Bevacizumab-Bevacizumab-Ranibizumab Injection Series (Type: EXPERIMENTAL): Group 3 eyes were assigned to Bevacizumab-Bevacizumab-Ranibizumab (BBR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4, 8, 12, 16 and 20 (periods 1 and 2), then crossed over to receive intravitreal injections of ranibizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye.
- Group 4 - Bevacizumab-Ranibizumab-Ranibizumab Injection Series (Type: EXPERIMENTAL): Group 4 eyes were assigned to Bevacizumab-Ranibizumab-Ranibizumab (BRR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of ranibizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).